Crinetics Pharmaceuticals (CRNX) Net Income towards Common Stockholders (2017 - 2026)

Crinetics Pharmaceuticals' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$249.3 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 357.58% year-over-year to -$249.3 million in Q1 2026; TTM through Mar 2026 was -$386.4 million, a 2982.01% decrease from a year earlier, with the FY2025 full-year figure at -$465.3 million, down 56.18% from the prior year.
• Net Income towards Common Stockholders declined to -$249.3 million in Q1 2026 per CRNX's latest filing, from -$122.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $115.6 million in Q2 2025 and bottomed at -$362.8 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is $42.4 million (2022), against an average of -$20.8 million.
• Across the five-year window, Net Income towards Common Stockholders soared 124.39% in 2022 and tumbled 906.31% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $45.0 million in 2022, then tumbled by 906.31% to -$362.8 million in 2023, then jumped by 77.78% to -$80.6 million in 2024, then tumbled by 52.16% to -$122.6 million in 2025, then plunged by 103.26% to -$249.3 million in 2026.
• Per Business Quant, the three latest CRNX Net Income towards Common Stockholders figures stand at -$249.3 million (Q1 2026), -$122.6 million (Q4 2025), and -$130.1 million (Q3 2025).